Pentixapharm Holding AG (FRA:PTP) Stock Based Compensation: €0.00 Mil (TTM As of Mar. 2026)


FRA:PTP Pentixapharm Holding AG FRA:PTP
20 GF Score
Price €2.20
! 2 Warning Signs
View Full Analysis

What is Pentixapharm Holding AG Stock Based Compensation?

Pentixapharm Holding AG FRA:PTP -4.35% 20 Stock Based Compensation is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:PTP with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Pentixapharm Holding AG's Stock Based Compensation for the three months ended in Mar. 2026 was €0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Pentixapharm Holding AG Stock Based Compensation Related Terms

Pentixapharm Holding AG Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Pentixapharm Holding AG's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pentixapharm Holding AG Stock Based Compensation Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
0.00 0.00 0.00 0.00 0.00

Pentixapharm Holding AG Quarterly Data
Dec21 Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:PTP
20GF Score
Pentixapharm Holding AG FRA:PTP
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pentixapharm Holding AG Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

What does a Stock Based Compensation of €0.00 Mil mean?
Pentixapharm Holding AG (FRA:PTP) has a Stock Based Compensation of €0.00 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Pentixapharm Holding AG and its competitors.
Is Pentixapharm Holding AG's Stock Based Compensation too high?
Pentixapharm Holding AG's current Stock Based Compensation is €0.00 Mil. Overall, Pentixapharm Holding AG has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's Stock Based Compensation compare to VRTX and REGN?
Pentixapharm Holding AG's Stock Based Compensation of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Pentixapharm Holding AG and its competitors. Pentixapharm Holding AG's current Stock Based Compensation is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (FRA:PTP) has a current Stock Based Compensation of €0.00 Mil. The current Stock Based Compensation is €0.00 Mil. Pentixapharm Holding AG's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Pentixapharm Holding AG (FRA:PTP), the current Stock Based Compensation is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pentixapharm Holding AG Business Description

Other Exchanges PTP:GermanyPTPN:Austria
Address Robert-Rossle-Street 10, Berlin, DEU, 13125
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
20GF Score

Get the complete analysis for FRA:PTP

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.20
Price